⚯ Click on each item to view
⚯ Zhu S, Gilbert JC, Hatala P, et al. The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer. J Thromb Haemost. 2020; 18: 1113–1123.
⚯ Zhu S, Gilbert JC, Liang Z, et al. Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200. J Thromb Haemost. 2020; 18: 1695– 1704.
⚯ Kovacevic KD, Grafeneder J, Schörgenhofer C, et al. The von Willebrand Factor A-1 domain binding aptamer BT200 elevates plasma levels of VWF and Factor VIII: a first-in-human trial. Haematologica. 2022; 107(9): September, 2022.
⚯ Cécile V. Denis and Peter J. Lenting. How to keep the FVIII/VWF complex in the circulation. Haematologica. 2022; 107(9): 2011–2013.
⚯ Ay C, Pabinger IP, Kovacevic KD, et al. The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease. Blood Adv. 2022; 6(18): 5467-5476.
⚯ Ay C, Kovacevic KD, Kraemmer D, et al. von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A. Blood. 2022.
BT200, a novel von Willebrand Factor (vWF) binding aptamer for bleeding disorders. Zhu S, et al TIDES Europe 2021.
Aptamer-Drug Conjugates (ApDC’s): Using the “chemical antibody” to target cancer biomarkers and kill tumor cells. Christina M, Novel Format Conjugates Summit 2022.
© 2023 Guardian Therapeutics. All rights reserved.
Welcome to the Guardian Therapeutics and Band Therapeutics website. We do not use any cookies or other technologies on this website, except those that are strictly necessary to enable normal functioning of this web page. View our data protection statement.
Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580
General Inquiries:
info@guardian-rx.com
Business Development Inquiries: businessdevelopment@guardian-rx.com